Pharmacological targeting of endoplasmic reticulum stress signaling in cancer

Biochemical Pharmacology

Volumn 85, Issue 5, 2013, Pages 653-666

  Schönthal, Axel H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Autophagy; Chemoresistance; GRP78 inhibitors; Yin Yang principle

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; BORTEZOMIB; BREFELDIN A; CALCIMYCIN; CELECOXIB; CHLOROQUINE; DEOXYGLUCOSE; DITHIOTHREITOL; GELDANAMYCIN; IONOMYCIN; MERCAPTOETHANOL; NELFINAVIR; THAPSIGARGIN; TUNICAMYCIN;

CANCER THERAPY; CELL SURVIVAL; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; HUMAN; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84873409612     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.09.012     Document Type: Review

References (195)

1. B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Rogerts, and P. Walter Molecular biology of the cell 2008 Garland Science New York
2. I. Braakman, and N.J. Bulleid Protein folding and modification in the mammalian endoplasmic reticulum Annu Rev Biochem 80 2011 71 99
3. J.D. Malhotra, and R.J. Kaufman The endoplasmic reticulum and the unfolded protein response Semin Cell Dev Biol 18 2007 716 731
4. D. Ron, and P. Walter Signal integration in the endoplasmic reticulum unfolded protein response Nat Rev Mol Cell Biol 8 2007 519 529
5. S. Bernales, K.L. McDonald, and P. Walter Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response PLoS Biol 4 2006 e423
6. W.X. Ding, H.M. Ni, W. Gao, Y.F. Hou, M.A. Melan, and X. Chen Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival J Biol Chem 282 2007 4702 4710
7. M. Ogata, S. Hino, A. Saito, K. Morikawa, S. Kondo, and S. Kanemoto Autophagy is activated for cell survival after endoplasmic reticulum stress Mol Cell Biol 26 2006 9220 9231
8. T. Yorimitsu, U. Nair, Z. Yang, and D.J. Klionsky Endoplasmic reticulum stress triggers autophagy J Biol Chem 281 2006 30299 30304
9. J.J. Yin, Y.B. Li, Y. Wang, G.D. Liu, J. Wang, and X.O. Zhu The role of autophagy in endoplasmic reticulum stress-induced pancreatic beta cell death Autophagy 8 2012 158 164
10. D.R. Fels, and C. Koumenis The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth Cancer Biol Ther 5 2006 723 728
11. D. Ron, and S.R. Hubbard How IRE1 reacts to ER stress Cell 132 2008 24 26
12. T. Sommer, and E. Jarosch BiP binding keeps ATF6 at bay Dev Cell 3 2002 1 2
13. V.M. Parmar, and M. Schroder Sensing endoplasmic reticulum stress Adv Exp Med Biol 738 2012 153 168
14. A.S. Lee GRP78 induction in cancer: therapeutic and prognostic implications Cancer Res 67 2007 3496 3499
15. M. Ni, Y. Zhang, and A.S. Lee Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting Biochem J 434 2011 181 188
16. H. Nishitoh CHOP is a multifunctional transcription factor in the ER stress response J Biochem 151 2012 217 219
17. D.T. Rutkowski, S.M. Arnold, C.N. Miller, J. Wu, J. Li, and K.M. Gunnison Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins PLoS Biol 4 2006 e374
18. E. Kojima, A. Takeuchi, M. Haneda, A. Yagi, T. Hasegawa, and K. Yamaki The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress: elucidation by GADD34-deficient mice FASEB J 17 2003 1573 1575
19. A.L. Shaffer, M. Shapiro-Shelef, N.N. Iwakoshi, A.H. Lee, S.B. Qian, and H. Zhao XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation Immunity 21 2004 81 93
20. Y. Adachi, K. Yamamoto, T. Okada, H. Yoshida, A. Harada, and K. Mori ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic reticulum Cell Struct Funct 33 2008 75 89
21. C. Hetz The unfolded protein response: controlling cell fate decisions under ER stress and beyond Nat Rev Mol Cell Biol 13 2012 89 102
22. G.C. Shore, F.R. Papa, and S.A. Oakes Signaling cell death from the endoplasmic reticulum stress response Curr Opin Cell Biol 23 2011 143 149
23. I. Tabas, and D. Ron Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress Nat Cell Biol 13 2011 184 190
24. R. Jäger, M.J. Bertrand, A.M. Gorman, P. Vandenabeele, and A. Samali The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress Biol Cell 104 2012 259 270
25. B. Luo, and A.S. Lee The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies Oncogene 2012 April 16 [Epub ahead of print]
26. S.H. Back, and R.J. Kaufman Endoplasmic reticulum stress and type 2 diabetes Annu Rev Biochem 81 2012 767 793
27. J.J. Hoozemans, and W. Scheper Endoplasmic reticulum: the unfolded protein response is tangled in neurodegeneration Int J Biochem Cell Biol 44 2012 1295 1298
28. R.L. Vidal, and C. Hetz Crosstalk between the UPR and autophagy pathway contributes to handling cellular stress in neurodegenerative disease Autophagy 2012 June 1 [Epub ahead of print]
29. L. Dara, C. Ji, and N. Kaplowitz The contribution of endoplasmic reticulum stress to liver diseases Hepatology 53 2011 1752 1763
30. H. Malhi, and R.J. Kaufman Endoplasmic reticulum stress in liver disease J Hepatol 54 2011 795 809
31. S.Z. Hasnain, R. Lourie, I. Das, A.C. Chen, and M.A. McGuckin The interplay between endoplasmic reticulum stress and inflammation Immunol Cell Biol 90 2012 260 270
32. I. Kim, W. Xu, and J.C. Reed Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities Nat Rev Drug Discov 7 2008 1013 1030
33. A.S. Lee, A. Delegeane, and D. Scharff Highly conserved glucose-regulated protein in hamster and chicken cells: preliminary characterization of its cDNA clone Proc Natl Acad Sci USA 78 1981 4922 4925
34. P.P. Hsu, and D.M. Sabatini Cancer cell metabolism: Warburg and beyond Cell 134 2008 703 707
35. G. Kroemer, and J. Pouyssegur Tumor cell metabolism: cancer's Achilles' heel Cancer Cell 13 2008 472 482
36. R.J. Shaw Glucose metabolism and cancer Curr Opin Cell Biol 18 2006 598 608
37. P. Pyrko, A.H. Schönthal, F.M. Hofman, T.C. Chen, and A.S. Lee The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas Cancer Res 67 2007 9809 9816
38. H.R. Christofk, M.G. Vander Heiden, M.H. Harris, A. Ramanathan, R.E. Gerszten, and R. Wei The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth Nature 452 2008 230 233
39. E. Lee, P. Nichols, D. Spicer, S. Groshen, M.C. Yu, and A.S. Lee GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer Cancer Res 66 2006 7849 7853
40. J.J. Virrey, D. Dong, C. Stiles, J.B. Patterson, L. Pen, and M. Ni Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells Mol Cancer Res 6 2008 1268 1275
41. J. Wang, Y. Yin, H. Hua, M. Li, T. Luo, and L. Xu Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response J Cell Mol Med 13 2009 3888 3897
42. P.M. Fernandez, S.O. Tabbara, L.K. Jacobs, F.C. Manning, T.N. Tsangaris, and A.M. Schwartz Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions Breast Cancer Res Treat 59 2000 15 26
43. Y. Fu, and A.S. Lee Glucose regulated proteins in cancer progression, drug resistance and immunotherapy Cancer Biol Ther 5 2006 741 744
44. G. Gazit, J. Lu, and A.S. Lee De-regulation of GRP stress protein expression in human breast cancer cell lines Breast Cancer Res Treat 54 1999 135 146
45. S. Oyadomari, and M. Mori Roles of CHOP/GADD153 in endoplasmic reticulum stress Cell Death Differ 11 2004 381 389
46. M. Boyce, and J. Yuan Cellular response to endoplasmic reticulum stress: a matter of life or death Cell Death Differ 13 2006 363 373
47. T. Suzuki, J. Lu, M. Zahed, K. Kita, and N. Suzuki Reduction of GRP78 expression with siRNA activates unfolded protein response leading to apoptosis in HeLa cells Arch Biochem Biophys 468 2007 1 14
48. Y. Ma, J.W. Brewer, J.A. Diehl, and L.M. Hendershot Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response J Mol Biol 318 2002 1351 1365
49. K.D. McCullough, J.L. Martindale, L.O. Klotz, T.Y. Aw, and N.J. Holbrook Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state Mol Cell Biol 21 2001 1249 1259
50. S.J. Marciniak, C.Y. Yun, S. Oyadomari, I. Novoa, Y. Zhang, and R. Jungreis CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum Genes Dev 18 2004 3066 3077
51. S.J. Healy, A.M. Gorman, P. Mousavi-Shafaei, S. Gupta, and A. Samali Targeting the endoplasmic reticulum-stress response as an anticancer strategy Eur J Pharmacol 625 2009 234 246
52. A.H. Schönthal Endoplasmic reticulum stress and autophagy as targets for cancer therapy Cancer Lett 275 2009 163 169
53. T. Beddoe, A.W. Paton, J. Le Nours, J. Rossjohn, and J.C. Paton Structure, biological functions and applications of the AB5 toxins Trends Biochem Sci 35 2010 411 418
54. A.W. Paton, T. Beddoe, C.M. Thorpe, J.C. Whisstock, M.C. Wilce, and J. Rossjohn AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP Nature 443 2006 548 552
55. J.M. Backer, A.V. Krivoshein, C.V. Hamby, J. Pizzonia, K.S. Gilbert, and Y.S. Ray Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells Neoplasia 11 2009 1165 1173
56. Y. Zhou, and A.S. Lee Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy J Natl Cancer Inst 90 1998 381 388
57. M. Hong, M.Y. Lin, J.M. Huang, P. Baumeister, S. Hakre, and A.L. Roy Transcriptional regulation of the Grp78 promoter by endoplasmic reticulum stress: role of TFII-I and its tyrosine phosphorylation J Biol Chem 280 2005 16821 16828
58. U.K. Misra, F. Wang, and S.V. Pizzo Transcription factor TFII-I causes transcriptional upregulation of GRP78 synthesis in prostate cancer cells J Cell Biochem 106 2009 381 389
59. S.P. Ermakova, B.S. Kang, B.Y. Choi, H.S. Choi, T.F. Schuster, and W.Y. Ma (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78 Cancer Res 66 2006 9260 9269
60. H-R. Park, K. Furihata, Y. Hayakawa, and K. Shin-ya Versipelostatin, a novel GRP78/Bip molecular chaperone down-regulator of microbial origin Tetrahedron Lett 43 2002 6941 6945
61. Y. Umeda, S. Chijiwa, K. Furihata, S. Sakuda, H. Nagasawa, and H. Watanabe Prunustatin A, a novel GRP78 molecular chaperone down-regulator isolated from Streptomyces violaceoniger J Antibiot (Tokyo) 58 2005 206 209
62. Y. Hayakawa, Y. Hattori, T. Kawasaki, K. Kanoh, K. Adachi, and Y. Shizuri Efrapeptin J, a new down-regulator of the molecular chaperone GRP78 from a marine Tolypocladium sp J Antibiot (Tokyo) 61 2008 365 371
63. H.R. Park, I.J. Ryoo, S.J. Choo, J.H. Hwang, J.Y. Kim, and M.R. Cha Glucose-deprived HT-29 human colon carcinoma cells are sensitive to verrucosidin as a GRP78 down-regulator Toxicology 229 2007 253 261
64. S.J. Choo, H.R. Park, I.J. Ryoo, J.P. Kim, B.S. Yun, and C.J. Kim Deoxyverrucosidin, a novel GRP78/BiP down-regulator, produced by Penicillium sp J Antibiot (Tokyo) 58 2005 210 213
65. J.H. Hwang, J.Y. Kim, M.R. Cha, I.J. Ryoo, S.J. Choo, and S.M. Cho Etoposide-resistant HT-29 human colon carcinoma cells during glucose deprivation are sensitive to piericidin A, a GRP78 down-regulator J Cell Physiol 215 2008 243 250
66. J.Y. Kim, J.H. Hwang, M.R. Cha, M.Y. Yoon, E.S. Son, and A. Tomida Arctigenin blocks the unfolded protein response and shows therapeutic antitumor activity J Cell Physiol 224 2010 33 40
67. D.H. Yu, J. Macdonald, G. Liu, A.S. Lee, M. Ly, and T. Davis Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy PLoS One 3 2008 e3951
68. S. Saito, A. Furuno, J. Sakurai, A. Sakamoto, H.R. Park, and K. Shin-Ya Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation Cancer Res 69 2009 4225 4234
69. B. Martin-Castillo, A. Vazquez-Martin, C. Oliveras-Ferraros, and J.A. Menendez Metformin and cancer. Doses, mechanisms and the dandelion and hormetic phenomena Cell Cycle 9 2010 1057 1064
70. B.N. Singh, S. Shankar, and R.K. Srivastava Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications Biochem Pharmacol 82 2011 1807 1821
71. S. Banerjee, Y. Li, Z. Wang, and F.H. Sarkar Multi-targeted therapy of cancer by genistein Cancer Lett 269 2008 226 242
72. M.A. Pierotti, F. Berrino, M. Gariboldi, C. Melani, A. Mogavero, and T. Negri Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects Oncogene 2012 June 4 [Epub ahead of print]
73. M. Ni, H. Zhou, S. Wey, P. Baumeister, and A.S. Lee Regulation of PERK signaling and leukemic cell survival by a novel cytosolic isoform of the UPR regulator GRP78/BiP PLoS One 4 2009 e6868
74. A. Matsumoto, and P.C. Hanawalt Histone H3 and heat shock protein GRP78 are selectively cross-linked to DNA by photoactivated gilvocarcin V in human fibroblasts Cancer Res 60 2000 3921 3926
75. F.C. Sun, S. Wei, C.W. Li, Y.S. Chang, C.C. Chao, and Y.K. Lai Localization of GRP78 to mitochondria under the unfolded protein response Biochem J 396 2006 31 39
76. M.A. Arap, J. Lahdenranta, P.J. Mintz, A. Hajitou, A.S. Sarkis, and W. Arap Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands Cancer Cell 6 2004 275 284
77. U.K. Misra, R. Deedwania, and S.V. Pizzo Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78 J Biol Chem 281 2006 13694 13707
78. G. Shani, W.H. Fischer, N.J. Justice, J.A. Kelber, W. Vale, and P.C. Gray GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth Mol Cell Biol 28 2008 666 677
79. Y. Zhang, R. Liu, M. Ni, P. Gill, and A.S. Lee Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP J Biol Chem 285 2010 15065 15075
80. Y. Liu, S.C. Steiniger, Y. Kim, G.F. Kaufmann, B. Felding-Habermann, and K.D. Janda Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery Mol Pharm 4 2007 435 447
81. S. Thomas, N. Sharma, E.B. Golden, H. Cho, P. Agarwal, and K.J. Gaffney Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors Cancer Lett 325 2012 63 71
82. A. Kardosh, E.B. Golden, P. Pyrko, J. Uddin, F.M. Hofman, and T.C. Chen Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib Cancer Res 68 2008 843 851
83. P. Pyrko, A. Kardosh, Y.T. Liu, N. Soriano, W. Xiong, and R.H. Chow Calcium-activated ER stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib (DMC), a non-coxib analog of celecoxib Mol Cancer Ther 6 2007 1262 1275
84. P. Pyrko, A. Kardosh, W. Wang, W. Xiong, A.H. Schönthal, and T.C. Chen HIV protease inhibitors nelfinavir and atazanavir induce glioblastoma cell death by triggering endoplasmic reticulum (ER) stress Cancer Res 67 2007 10920 10928
85. K.M. Livesey, D. Tang, H.J. Zeh, and M.T. Lotze Autophagy inhibition in combination cancer treatment Curr Opin Investig Drugs 10 2009 1269 1279
86. H.Y. Cho, S. Thomas, E.B. Golden, K.J. Gaffney, F.M. Hofman, and T.C. Chen Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress Cancer Lett 282 2009 87 97
87. W.J. Welch The mammalian heat shock (or stress) response: a cellular defense mechanism Adv Exp Med Biol 225 1987 287 304
88. H.R. Pelham Speculations on the functions of the major heat shock and glucose-regulated proteins Cell 46 1986 959 961
89. H.L. Pahl Signal transduction from the endoplasmic reticulum to the cell nucleus Physiol Rev 79 1999 683 701
90. J.J. Gills, J. Lopiccolo, J. Tsurutani, R.H. Shoemaker, C.J. Best, and M.S. Abu-Asab Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo Clin Cancer Res 13 2007 5183 5194
91. W.B. Bernstein, and P.A. Dennis Repositioning HIV protease inhibitors as cancer therapeutics Curr Opin HIV AIDS 3 2008 666 675
92. A. Brüning, A. Gingelmaier, K. Friese, and I. Mylonas New prospects for nelfinavir in non-HIV-related diseases Curr Mol Pharmacol 3 2010 91 97
93. M. Treiman, C. Caspersen, and S.B. Christensen A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases Trends Pharmacol Sci 19 1998 131 135
94. A.M. Winther, H. Liu, Y. Sonntag, C. Olesen, M. le Maire, and H. Soehoel Critical roles of hydrophobicity and orientation of side chains for inactivation of sarcoplasmic reticulum Ca2+-ATPase with thapsigargin and thapsigargin analogs J Biol Chem 285 2010 28883 28892
95. H. Hakii, H. Fujiki, M. Suganuma, M. Nakayasu, T. Tahira, and T. Sugimura Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanoylphorbol-13- acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis J Cancer Res Clin Oncol 111 1986 177 181
96. K. Ohuchi, C. Takahashi, N. Hirasawa, M. Watanabe, H. Fujiki, and S. Tsurufuji Stimulation of histamine release and arachidonic acid metabolism in rat peritoneal mast cells by thapsigargin, a non-TPA-type tumor promoter Biochim Biophys Acta 1003 1989 9 14
97. S.B. Christensen, D.M. Skytte, S.R. Denmeade, C. Dionne, J.V. Moller, and P. Nissen A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells Anticancer Agents Med Chem 9 2009 276 294
98. S.R. Denmeade, C.M. Jakobsen, S. Janssen, S.R. Khan, E.S. Garrett, and H. Lilja Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer J Natl Cancer Inst 95 2003 990 1000
99. S.R. Denmeade, A.M. Mhaka, D.M. Rosen, W.N. Brennen, S. Dalrymple, and I. Dach Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy Sci Transl Med 4 2012 140ra86
100. D. Duksin, and W.C. Mahoney Relationship of the structure and biological activity of the natural homologues of tunicamycin J Biol Chem 257 1982 3105 3109
101. A.D. Elbein The tunicamycins-useful tools for studies on glycoproteins Trends Biochem Sci 6 1981 219 221
102. J.N. Contessa, M.S. Bhojani, H.H. Freeze, A. Rehemtulla, and T.S. Lawrence Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells Cancer Res 68 2008 3803 3809
103. Y.H. Ling, T. Li, R. Perez-Soler, and M. Haigentz Jr. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib Cancer Chemother Pharmacol 64 2009 539 548
104. J.N. Contessa, M.S. Bhojani, H.H. Freeze, B.D. Ross, A. Rehemtulla, and T.S. Lawrence Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy Clin Cancer Res 16 2010 3205 3214
105. I. Noda, S. Fujieda, M. Seki, N. Tanaka, H. Sunaga, and T. Ohtsubo Inhibition of N-linked glycosylation by tunicamycin enhances sensitivity to cisplatin in human head-and-neck carcinoma cells Int J Cancer 80 1999 279 284
106. T. Shiraishi, T. Yoshida, S. Nakata, M. Horinaka, M. Wakada, and Y. Mizutani Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells Cancer Res 65 2005 6364 6370
107. C.C. Jiang, L.H. Chen, S. Gillespie, K.A. Kiejda, N. Mhaidat, and Y.F. Wang Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response Cancer Res 67 2007 5880 5888
108. X. Zhang, T. Inukai, K. Akahane, K. Hirose, I. Kuroda, and H. Honna Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis Leuk Res 35 2011 940 949
109. H.Y. Zhang, Z.X. Du, B.Q. Liu, Y.Y. Gao, X. Meng, and Y. Guan Tunicamycin enhances TRAIL-induced apoptosis by inhibition of cyclin D1 and the subsequent downregulation of survivin Exp Mol Med 41 2009 362 369
110. L.J. Zhang, Z.Q. Li, Y.P. Yang, X.W. Li, and J.F. Ji Tunicamycin suppresses cisplatin-induced HepG2 cell apoptosis via enhancing p53 protein nuclear export Mol Cell Biochem 327 2009 171 182
111. J.L. Hsu, P.C. Chiang, and J.H. Guh Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78 Naunyn Schmiedebergs Arch Pharmacol 380 2009 373 382
112. G.L. Beretta, V. Benedetti, G. Cossa, Y.G. Assaraf, E. Bram, and L. Gatti Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin Biochem Pharmacol 79 2010 1108 1117
113. D. Hiss, G. Gabriels, P. Jacobs, and P. Folb Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines Eur J Cancer 32A 1996 2164 2172
114. J.S. Lee, Z. Zheng, R. Mendez, S.W. Ha, Y. Xie, and K. Zhang Pharmacologic ER stress induces non-alcoholic steatohepatitis in an animal model Toxicol Lett 211 2012 29 38
115. A. Banerjee, J.Y. Lang, M.C. Hung, K. Sengupta, S.K. Banerjee, and K. Baksi Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin J Biol Chem 286 2011 29127 29138
116. J.E. Casanova Regulation of Arf activation: the Sec7 family of guanine nucleotide exchange factors Traffic 8 2007 1476 1485
117. M. Chami, B. Oules, G. Szabadkai, R. Tacine, R. Rizzuto, and P. Paterlini-Brechot Role of SERCA1 truncated isoform in the proapoptotic calcium transfer from ER to mitochondria during ER stress Mol Cell 32 2008 641 651
118. J.L. Moon, S.Y. Kim, S.W. Shin, and J.W. Park Regulation of brefeldin A-induced ER stress and apoptosis by mitochondrial NADP(+)-dependent isocitrate dehydrogenase Biochem Biophys Res Commun 417 2012 760 764
119. B.D. Price, L.A. Mannheim-Rodman, and S.K. Calderwood Brefeldin A, thapsigargin, and AIF4- stimulate the accumulation of GRP78 mRNA in a cycloheximide dependent manner, whilst induction by hypoxia is independent of protein synthesis J Cell Physiol 152 1992 545 552
120. D. Wlodkowic, J. Skommer, and J. Pelkonen Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells Leuk Res 31 2007 1687 1700
121. E.S. Liu, J.H. Ou, and A.S. Lee Brefeldin A as a regulator of grp78 gene expression in mammalian cells J Biol Chem 267 1992 7128 7133
122. J.S. Carew, S.T. Nawrocki, Y.V. Krupnik, K. Dunner Jr., D.J. McConkey, and M.J. Keating Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL Blood 107 2006 222 231
123. P. Boya, I. Cohen, N. Zamzami, H.L. Vieira, and G. Kroemer Endoplasmic reticulum stress-induced cell death requires mitochondrial membrane permeabilization Cell Death Differ 9 2002 465 467
124. Y.A. Yeh, and G. Weber Growth inhibitory action of brefeldin A with taxol and tiazofurin in human breast carcinoma cells Cancer Biochem Biophys 15 1995 11 17
125. J.H. Choi, A.Y. Choi, H. Yoon, W. Choe, K.S. Yoon, and J. Ha Baicalein protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stress-induced apoptosis through inhibition of reactive oxygen species production and CHOP induction Exp Mol Med 42 2010 811 822
126. P. Chardin, and F. McCormick Brefeldin A: the advantage of being uncompetitive Cell 97 1999 153 155
127. A. Peyroche, B. Antonny, S. Robineau, J. Acker, J. Cherfils, and C.L. Jackson Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain Mol Cell 3 1999 275 285
128. L.R. Phillips, T.L. Wolfe, L. Malspeis, and J.G. Supko Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detection J Pharm Biomed Anal 16 1998 1301 1309
129. A.T. Koki, and J.L. Masferrer Celecoxib: a specific COX-2 inhibitor with anticancer properties Cancer Control 9 2002 28 35
130. S. Grösch, T.J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors J Natl Cancer Inst 98 2006 736 747
131. A.H. Schönthal Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy Br J Cancer 97 2007 1465 1468
132. K. Kashfi, and B. Rigas Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention Biochem Pharmacol 70 2005 969 986
133. J.M. Dogne, A. Thiry, and C.T. Supuran Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs Curr Pharm Des 14 2008 679 684
134. A.J. Johnson, A.L. Hsu, H.P. Lin, X. Song, and C.S. Chen The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks Biochem J 366 2002 831 837
135. A.H. Schönthal, T.C. Chen, F.M. Hofman, S.G. Louie, and N.A. Petasis Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs Expert Opin Investig Drugs 17 2008 197 208
136. A.H. Schönthal, T.C. Chen, F.M. Hofman, S.G. Louie, and N.A. Petasis Preclinical development of novel anti-tumor drugs targeting the endoplasmic reticulum stress response Curr Pharm Des 17 2011 2428 2438
137. J. Adams, and M. Kauffman Development of the proteasome inhibitor Velcade (Bortezomib) Cancer Invest 22 2004 304 311
138. T. Mujtaba, and Q.P. Dou Advances in the understanding of mechanisms and therapeutic use of bortezomib Discov Med 12 2011 471 480
139. A.M. Roccaro, T. Hideshima, P.G. Richardson, D. Russo, D. Ribatti, and A. Vacca Bortezomib as an antitumor agent Curr Pharm Biotechnol 7 2006 441 448
140. D.R. Fels, J. Ye, A.T. Segan, S.J. Kridel, M. Spiotto, and M. Olson Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways Cancer Res 68 2008 9323 9330
141. A. Fribley, Q. Zeng, and C.Y. Wang Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells Mol Cell Biol 24 2004 9695 9704
142. S.T. Nawrocki, J.S. Carew, K. Dunner Jr., L.H. Boise, P.J. Chiao, and P. Huang Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells Cancer Res 65 2005 11510 11519
143. S.T. Nawrocki, J.S. Carew, M.S. Pino, R.A. Highshaw, K. Dunner Jr., and P. Huang Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis Cancer Res 65 2005 11658 11666
144. N. Mimura, M. Fulciniti, G. Gorgun, Y.T. Tai, D. Cirstea, and L. Santo Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma Blood 119 2012 5772 5781
145. D.R. Carrasco, K. Sukhdeo, M. Protopopova, R. Sinha, M. Enos, and D.E. Carrasco The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis Cancer Cell 11 2007 349 360
146. C.C. Jiang, L.H. Chen, S. Gillespie, Y.F. Wang, K.A. Kiejda, and X.D. Zhang Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis Cancer Res 67 2007 9750 9761
147. E.A. Obeng, L.M. Carlson, D.M. Gutman, W.J. Harrington Jr., K.P. Lee, and L.H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 2006 4907 4916
148. M. Chen, G.J. Gutierrez, and Z.A. Ronai Ubiquitin-recognition protein Ufd1 couples the endoplasmic reticulum (ER) stress response to cell cycle control Proc Natl Acad Sci USA 108 2011 9119 9124
149. S. Meister, U. Schubert, K. Neubert, K. Herrmann, R. Burger, and M. Gramatzki Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition Cancer Res 67 2007 1783 1792
150. A. Brüning Analysis of nelfinavir-induced endoplasmic reticulum stress Methods Enzymol 491 2011 127 142
151. A. Brüning, P. Burger, M. Vogel, M. Rahmeh, A. Gingelmaiers, and K. Friese Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis Cancer Biol Ther 8 2009 226 232
152. L. Sun, L. Niu, X. Zhu, J. Hao, P. Wang, and H. Wang Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells J Chemother 24 2012 161 166
153. M. Piccinini, M.T. Rinaudo, A. Anselmino, B. Buccinna, C. Ramondetti, and A. Dematteis The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function Antivir Ther 10 2005 215 223
154. W. Jiang, P.J. Mikochik, J.H. Ra, H. Lei, K.T. Flaherty, and J.D. Winkler HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest Cancer Res 67 2007 1221 1227
155. A. Bruning, M. Vogel, I. Mylonas, K. Friese, and A. Burges Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir Curr Cancer Drug Targets 11 2011 799 809
156. A.K. Gupta, B. Li, G.J. Cerniglia, M.S. Ahmed, S.M. Hahn, and A. Maity The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response Neoplasia 9 2007 271 278
157. A. Brüning, K. Friese, A. Burges, and I. Mylonas Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells Breast Cancer Res 12 2010 R45
158. X. Tian, J. Ye, M. Alonso-Basanta, S.M. Hahn, C. Koumenis, and J.F. Dorsey Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) J Biol Chem 286 2011 29408 29416
159. A. Bruning, M. Vogel, P. Burger, M. Rahmeh, A. Gingelmaier, and K. Friese Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells Biochem Biophys Res Commun 377 2008 1309 1314
160. J. Zeng, A.P. See, K. Aziz, S. Thiyagarajan, T. Salih, and R.P. Gajula Nelfinavir induces radiation sensitization in pituitary adenoma cells Cancer Biol Ther 12 2011 657 663
161. K.C. Cuneo, T. Tu, L. Geng, A. Fu, D.E. Hallahan, and C.D. Willey HIV protease inhibitors enhance the efficacy of irradiation Cancer Res 67 2007 4886 4893
162. A.K. Gupta, G.J. Cerniglia, R. Mick, W.G. McKenna, and R.J. Muschel HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo Cancer Res 65 2005 8256 8265
163. J. Gills, J. Lopiccolo, and P.A. Dennis Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy Autophagy 4 2008 107 109
164. R. Rengan, R. Mick, D. Pryma, M.A. Rosen, L.L. Lin, and A.M. Maity A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response J Thorac Oncol 7 2012 709 715
165. T.B. Brunner, M. Geiger, G.G. Grabenbauer, M. Lang-Welzenbach, T.S. Mantoni, and A. Cavallaro Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer J Clin Oncol 26 2008 2699 2706
166. J. Travers, S. Sharp, and P. Workman HSP90 inhibition: two-pronged exploitation of cancer dependencies Drug Discov Today 17 2012 242 252
167. L. Whitesell, and N.U. Lin HSP90 as a platform for the assembly of more effective cancer chemotherapy Biochim Biophys Acta 1823 2012 756 766
168. E.L. Davenport, H.E. Moore, A.S. Dunlop, S.Y. Sharp, P. Workman, and G.J. Morgan Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells Blood 110 2007 2641 2649
169. B. Lawson, J.W. Brewer, and L.M. Hendershot Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway J Cell Physiol 174 1998 170 178
170. A. Taiyab, and A.S. Sreedhar Rao Ch M. Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma Biochem Pharmacol 78 2009 142 152
171. M.G. Marcu, M. Doyle, A. Bertolotti, D. Ron, L. Hendershot, and L. Neckers Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha Mol Cell Biol 22 2002 8506 8513
172. M. Gorska, U. Popowska, A. Sielicka-Dudzin, A. Kuban-Jankowska, W. Sawczuk, and N. Knap Geldanamycin and its derivatives as Hsp90 inhibitors Front Biosci 17 2012 2269 2277
173. L. Neckers, and P. Workman Hsp90 molecular chaperone inhibitors: are we there yet Clin Cancer Res 18 2012 64 76
174. J.R. Porter, J. Ge, J. Lee, E. Normant, and K. West Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy Curr Top Med Chem 9 2009 1386 1418
175. K. Jhaveri, T. Taldone, S. Modi, and G. Chiosis Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Biochim Biophys Acta 1823 2012 742 755
176. A.H. Schönthal Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioblastoma therapy Neurosurg Focus 20 E21 2006 1 10
177. S. Tsutsumi, T. Gotoh, W. Tomisato, S. Mima, T. Hoshino, and H.J. Hwang Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis Cell Death Differ 11 2004 1009 1016
178. J.J. Virrey, A. Kardosh, E.G. Golden, S.G. Louie, N.A. Petasis, and A.H. Schönthal Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature Mol Cancer Ther 9 2010 631 641
179. J. Zhu, J.W. Huang, P.H. Tseng, Y.T. Yang, J. Fowble, and C.W. Shiau From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors Cancer Res 64 2004 4309 4318
180. L. Booth, S.C. Cazanave, H.A. Hamed, A. Yacoub, B. Ogretmen, and C.S. Chen OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing Cancer Biol Ther 13 2012 224 236
181. H.A. Hamed, A. Yacoub, M.A. Park, P. Eulitt, D. Sarkar, and I.P. Dimitrie OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins Cancer Biol Ther 9 2010 526 536
182. A. Yacoub, M.A. Park, D. Hanna, Y. Hong, C. Mitchell, and A.P. Pandya OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells Mol Pharmacol 70 2006 589 603
183. L.M. Porchia, M. Guerra, Y.C. Wang, Y. Zhang, A.V. Espinosa, and M. Shinohara 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] -phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase Mol Pharmacol 72 2007 1124 1131
184. S. Zhang, A. Suvannasankha, C.D. Crean, V.L. White, A. Johnson, and C.S. Chen OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms Clin Cancer Res 13 2007 4750 4758
185. P.H. Tseng, H.P. Lin, J. Zhu, K.F. Chen, E.M. Hade, and D.C. Young Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance Blood 105 2005 4021 4027
186. P.H. Tseng, Y.C. Wang, S.C. Weng, J.R. Weng, C.S. Chen, and R.W. Brueggemeier Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor Mol Pharmacol 70 2006 1534 1541
187. Y.C. Wang, S.K. Kulp, D. Wang, C.C. Yang, A.M. Sargeant, and J.H. Hung Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors Cancer Res 68 2008 2820 2830
188. S.C. Weng, Y. Kashida, S.K. Kulp, D. Wang, R.W. Brueggemeier, and C.L. Shapiro Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor Mol Cancer Ther 7 2008 800 808
189. F. Janku, D.J. McConkey, D.S. Hong, and R. Kurzrock Autophagy as a target for anticancer therapy Nat Rev Clin Oncol 8 2011 528 539
190. V.R. Solomon, and H. Lee Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies Eur J Pharmacol 625 2009 220 233
191. T. Kanzawa, I.M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells Cell Death Differ 11 2004 448 457
192. E. Briceno, A. Calderon, and J. Sotelo Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme Surg Neurol 67 2007 388 391
193. P.G. Richardson, C.S. Mitsiades, J.P. Laubach, S. Lonial, A.A. Chanan-Khan, and K.C. Anderson Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers Br J Haematol 152 2011 367 379
194. P.G. Richardson, A.A. Chanan-Khan, S. Lonial, A.Y. Krishnan, M.P. Carroll, and M. Alsina Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study Br J Haematol 153 2011 729 740
195. A. Kardosh, E.B. Golden, P. Pyrko, J. Uddin, F.M. Hofman, and C.T. Chen Aggravated endoplasmic reticulum (ER) stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analog, 2,5-dimethyl-celecoxib Cancer Res 68 2008 843 851